Savara Inc. (NASDAQ:SVRA) is one of the top long-term biotechnology stocks to buy. On October 2, Savara Inc. (NASDAQ:SVRA) announced that its partner, TrilliumBiO, will present data on the development of a dried-serum assay at the upcoming CHEST 2025 conference.
Copyright: djoronimo / 123RF Stock Photo
TrilliumBiO is developing a dried-serum assay to enhance the detection of GM-CSF antibodies and aid in diagnosing autoimmune pulmonary alveolar proteinosis (aPAP). Additionally, Savara is to make a presentation on its investigational treatment, molgramostim, a recombinant human GM-CSF, currently in Phase 3 development for aPAP.
The presentation focuses on the company delivering positive results from the Phase 3 IMPALA-2 trial of molgramostim for treating autoimmune pulmonary alveolar proteinosis (aPAP). The results underlined the treatment’s ability to enhance lung diffusing capacity.
Savara Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for rare respiratory diseases. Its lead product candidate is molgramostim (MOLBREEVI), an inhaled drug in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP), a rare lung disease.
READ NEXT: Billionaire Steve Cohen’s 10 Small-Cap Stock Picks with Huge Upside Potential and Top 9 Credit Services Stocks to Buy as the US Cuts Interest Rates.
This article is originally published at Insider Monkey.
